Thomas Smith
Stock Analyst at Leerink Partners
(2.12)
# 2,898
Out of 5,165 analysts
58
Total ratings
34.55%
Success rate
8.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGMB AgomAb Therapeutics NV | Initiates: Outperform | $36 | $14.32 | +151.48% | 1 | Mar 3, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $6.08 | +97.37% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $26.20 | +22.14% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $23.63 | +77.74% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $2.32 | -56.90% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $6.30 | +42.86% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $3.74 | +87.17% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $7.33 | +432.06% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $5.14 | +405.84% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $122.75 | -83.71% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $703.30 | -38.15% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $60.82 | -40.81% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.70 | +159.26% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $25.00 | -16.00% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $28.77 | +56.41% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $11.16 | -46.24% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.77 | +116.61% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.16 | +331.03% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $16.73 | +1.61% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $30.19 | +111.99% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.51 | +323.99% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.74 | +848.91% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $36.01 | -66.68% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $11.03 | +625.29% | 2 | Dec 8, 2020 |
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Outperform
Price Target: $36
Current: $14.32
Upside: +151.48%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $6.08
Upside: +97.37%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $26.20
Upside: +22.14%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $23.63
Upside: +77.74%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $2.32
Upside: -56.90%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $6.30
Upside: +42.86%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $3.74
Upside: +87.17%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $7.33
Upside: +432.06%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $5.14
Upside: +405.84%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $122.75
Upside: -83.71%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $703.30
Upside: -38.15%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $60.82
Upside: -40.81%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.70
Upside: +159.26%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $25.00
Upside: -16.00%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $28.77
Upside: +56.41%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $11.16
Upside: -46.24%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $2.77
Upside: +116.61%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.16
Upside: +331.03%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $16.73
Upside: +1.61%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $30.19
Upside: +111.99%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.51
Upside: +323.99%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.74
Upside: +848.91%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $36.01
Upside: -66.68%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $11.03
Upside: +625.29%